Bill Densel

COO at Temple Therapeutics

Mr. Densel has over 24 years of experience in the successful development and commercialization of innovative medical devices, including surgical instruments, diagnostics, and biomaterials. Bill was prevously serving as CEO of Check-Cap, Ltd, a medical diagnostics company developing an ingestible capsule system for colorectal cancer screening. Prior to that, Bill served as CEO of Beacon Endoscopic, a venture-backed company he led to a successful acquisition by Covidien. Prior to Beacon Endoscopic, Bill held positions with BG Medicine, Dune Medical Devices, Hologic Corporation, Boston Scientific Corporation, and Genzyme Biosurgery. Prior to his corporate career, Bill received a commission in the U.S. Navy and served four years as a Special Operations Officer. He attended the Amos Tuck School of Business at Dartmouth – Tuck Executive Program and holds a Bachelor of Arts in Economics from Duke University.


Org chart

No direct reports

Timeline

  • COO

    Current role